Výsledky vyhledávání - "Pamela A. Kelchlin"

In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model

Autor: Rachel L. Soon, Alan Forrest, Patricia N. Holden, Lawrence V. Friedrich, Zackery P Bulman, Judith N. Steenbergen, Justin R. Lenhard, Brian T. Tsuji, Pamela A. Kelchlin

Publikováno v: International Journal of Antimicrobial Agents. 49:25-30

The proliferation of multidrug-resistant Gram-negative pathogens has been exacerbated by a lack of novel agents in current development by pharmaceutical companies. Ceftolozane/tazobactam was recently approved by the FDA for the treatment of complicat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e2cfed669b49fca9866cacd784d28e7
https://doi.org/10.1016/j.ijantimicag.2016.07.015

Zobrazit plný text záznamu

Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam–β-Lactamase Inhibitor Combinations

Autor: Pamela A. Kelchlin, Patricia N. Holden, Brian T. Tsuji, Alan Forrest, Justin R. Lenhard, Rachel L. Soon, Judith N. Steenbergen, Lawrence V. Friedrich, Zackery P Bulman

Publikováno v: Antimicrobial Agents and Chemotherapy. 60:1967-1973

Despite a dearth of new agents currently being developed to combat multidrug-resistant Gram-negative pathogens, the combination of ceftolozane and tazobactam was recently approved by the Food and Drug Administration to treat complicated intra-abdomin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ffff95c2ef00582ddeee7e2c867d891
https://doi.org/10.1128/aac.02635-15

Zobrazit plný text záznamu

Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations

Autor: Patricia N. Holden, Brian T. Tsuji, Alan Forrest, Jürgen B. Bulitta, Tanya Brown, Pamela A. Kelchlin, Charles A. Peloquin, Debra Hanna, Laura A. Skerlos

Publikováno v: Journal of Antimicrobial Chemotherapy. 67:2182-2190

Objectives Vancomycin-resistant enterococci (VRE) have emerged as an important nosocomial pathogen in medical centres worldwide. This study evaluated the impact of front-loading of linezolid on bacterial killing and suppression of resistance against

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cec2d7f25de8e9128608f585106e00c
https://doi.org/10.1093/jac/dks201

Zobrazit plný text záznamu

Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of Staphylococcus aureus

Autor: Jürgen B. Bulitta, Alan Forrest, Patricia N. Holden, Debra Hanna, Tanya Brown, Charles A. Peloquin, Ridhi Parasrampuria, Pamela A. Kelchlin, Brian T. Tsuji, Daniel A. Brazeau

Front loading is a strategy used to optimize the pharmacodynamic profile of an antibiotic through the administration of high doses early in therapy for a short duration. Our aims were to evaluate the impact of front loading of linezolid regimens on b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a918bb8a1aa453f9118ba11c7566f0
https://europepmc.org/articles/PMC3393439/

Zobrazit plný text záznamu

In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus

Autor: Alan Forrest, Patrick F. Smith, Brian T. Tsuji, Jenny C Yang, Pamela A. Kelchlin

Publikováno v: The Journal of antimicrobial chemotherapy. 62(1)

Objectives ABI-0043 is a novel benzoxazinorifamycin derivative, which derives its potent bactericidal activity by the specific inhibition of bacterial RNA polymerase. We evaluated the in vitro pharmacodynamics and bactericidal activity of ABI-0043 ag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e7d129e032cbe22e5c7832dccac8b9
https://pubmed.ncbi.nlm.nih.gov/18400804

Zobrazit plný text záznamu

Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype▿

Autor: Brian T. Tsuji, Alan Forrest, Pamela A. Kelchlin, Christof von Eiff, Patrick F. Smith

The in vitro bactericidal activities of vancomycin against Staphylococcus aureus hemB mutants displaying the small-colony-variant phenotype and their parental strains were evaluated. Vancomycin killing activities against hemB mutants were markedly at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d113cfb01f065cbe497a1677ef76ded4
https://europepmc.org/articles/PMC2292514/

Zobrazit plný text záznamu

Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model

Autor: Brian T. Tsuji, Alan Forrest, Ronald N. Jones, Patrick F. Smith, Sujata M. Bhavnani, Sanela Bajic, Paul G. Ambrose, Pamela A. Kelchlin, Brent M. Booker

Publikováno v: Diagnostic microbiology and infectious disease. 56(4)

An in vitro pharmacodynamic model was used to determine the pharmacokinetic–pharmacodynamic (PK–PD) measure and magnitude most strongly related to cefprozil activity against Haemophilus influenzae . Using 3 clinical isolates of H. influenzae , a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd3e08ac9272a8ea1de2136c8def3ba
https://pubmed.ncbi.nlm.nih.gov/16930921

Zobrazit plný text záznamu

Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi

Autor: Sujata M. Bhavnani, Alan Forrest, Paul G. Ambrose, Julie M. Bullock, Ronald N. Jones, Patrick F. Smith, Pamela A. Kelchlin, Brent M. Booker

Publikováno v: Antimicrobial agents and chemotherapy. 49(5)

Salmonella enterica serotype Typhi and nontyphoidal Salmonella remain major causes of morbidity and mortality worldwide. Ampicillin, trimethoprim-sulfamethoxazole, and chloramphenicol no longer provide reliable coverage of Salmonella , and fluoroquin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3e978eda77b44a01b2993eccab38f61
https://pubmed.ncbi.nlm.nih.gov/15855495

Zobrazit plný text záznamu

OII-A-3PK/PD in silico and in vitro simulations of linezolid (LZD) activity against methicillin resistant staphylococcus aureus (MRSA)

Autor: S. Bilic, J. Z. Zack, Patrick F. Smith, Pamela A. Kelchlin, Alan Forrest

Publikováno v: Clinical Pharmacology & Therapeutics. 79:P4-P4

BACKGROUND To predict the activity of various LZD dosage regimens for MRSA. The MIC90 of LZD against MRSA is ∼4 mg/L. METHODS For 2 clinical MRSA isolates (MIC2, MIC4), 24h kill curve experiments were fit by a PD model: capacity limited replication

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::125d3d0717dcedd583285aa62bc1324a
https://doi.org/10.1016/j.clpt.2005.12.012

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání